Q-omics provides the consensus-scored IL13 profile across patient tissues and cancer cell-line models. IL13 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL13 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, IL13 RNA expression shows 11,539 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, BRCA, and UVM as cancer lineages where IL13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL13 survival associations across molecular data types. IL13 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL13 RNA expression–survival associations across cancer types. High IL13 expression shows unfavorable associations in THCA, DLBC, ACC, PRAD and THYM, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for IL13 RNA expression.
This table summarizes IL13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for IL13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL13 shows lower tumor expression in BRCA, LUAD, LUSC and KICH and higher tumor expression in COAD and KIRC. The BRCA box plot shows higher IL13 RNA expression in normal versus tumor tissue (log2 FC = −0.116, t-test p < 0.001).
This table shows molecular features associated with IL13 in patient tissues and cancer cell lines. In patient samples, IL13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
